世界临床医学·2011年6月 第5卷 第6期
priapism in sickle cell disease. Blood, 2005, 106: 3264–67
[80] Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade
in a cohort of infants with sickle cell disease. Blood, 1995; 86: 776–83[81] Hoppe C, Klitz W, D’Harlingue K, et al. Confirmation of an association
between TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke, 2007, 38: 2241–46
[82] Hoppe C, Klitz W, Cheng S, et al. Gene interactions and stroke risk in
children with sickle cell anemia. Blood, 2004, 103: 2391–96
[83] Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and
prognostic modeling of overt stroke in sickle cell anemia. Nat Genet, 2005, 37: 340–41
[84] Steinberg MH, Adewoye AB. Modifier genes and sickle cell anemia. Curr
Opin Hematol, 2006, 13: 131–36
[85] Redwood AM, Williams EM, Desai P, et al. Climate and painful crisis of
sickle-cell disease in Jamaica. BMJ, 1976, 1: 66–68
[86] Jones S, Duncan ER, Thomas N, et al. Windy weather and low humidity
are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol, 2005, 131: 530–33
[87] Yallop D, Duncan ER, Norris E, et al. The associations between air
quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol, 2007, 136: 844–48[88] Mittal H, Roberts L, Fuller GW, et al. The effects of air quality on
haematological and clinical parameters in children with sickle cell anaemia. Ann Hematol, 2009, 88: 529–33
[89] Ryan K, Bain B, Worthington D, et al. Significant haemoglobinopathies:
guidelines for screening and diagnosis. Br J Haematol, 2010, 149: 35–49[90] Vichinsky V, Hurst D, Earles A, et al. Newborn screening for sickle cell
disease: effect on mortality. Pediatrics, 1988, 81: 749–55
[91] Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal
hemoglobin production in sickle cell anaemia. J Clin Invest, 1984, 74: 652–56
[92] Cartron J-P, Elion J. Erythroid adhesion molecules in sickle cell disease:
effect of hydroxyurea. Transfus Clin Biol, 2008, 15: 39–50
[93] Lou TF, Singh M, Mackie A, et al. Hydroxyurea generates nitric oxide in
human erythroid cells: mechanisms for gamma-globin gene activation. Exp Biol Med, 2009, 234: 1374–82
[94] Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell
disease: a systematic review for efficacy and toxicity in children. Pediatrics, 2008, 122: 1332–42
[95] Lankron S, Stouse JJ, Wilson R, et al. Systematic review: hydroxyurea
for the treatment of adults with sickle cell disease. Ann Intern Med, 2008, 48: 939–55
[96] Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle
cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Hematologica, 2008, 93: 988–93
[97] Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and
pregnancy outcomes in sickle cell anemia. J Natl Med Assoc, 2009, 101: 1046–51
[98] Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on
mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA, 2003, 289: 1645–51
[99] Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged
administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 2010, 115: 2354–63
[100] Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy
462
lowers transcranial doppler flow velocities in children with sickle cell anemia. Blood, 2007, 110: 1043–47
[101] Singh SA, Koumbourlis AC, Aygun B. Resolution of chronic hypoxemia
in pediatric sickle cell patients after treatment with hydroxyurea. Pediatr Blood Cancer, 2008, 50: 1258–60
[102] Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy
for children with sickle nephropathy. Pediatr Blood Cancer, 2005, 45: 982–85
[103] Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of
Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008, 148: 932–38[104] Eckman JR. Techniques for blood administration in sickle cell patients.
Semin Hematol, 2001, 38: 23–29
[105] Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle
cell anaemia and transfusion of racially unmatched blood. N Engl J Med, 1990, 322: 1617–21
[106] Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in
transfusion-dependent thalassemia and sickle cell disease. Blood, 2004, 103: 1934–36
[107] Vichinsky E, Onyekwere O, Porter JB, et al. A randomised comparison
of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol, 2007, 136: 501–08[108] Bhatia M, Walters MC. Hematopoietic cell transplantation for
thalassaemia and sickle cell disease: past, present and future. Bone Marrow Transplant, 2008, 41: 109–17
[109] Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic
stem-cell transplantation for sickle cell disease. N Engl J Med, 2009, 361: 2309–17
[110] Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell
disease in transgenic mouse models by gene therapy. Science, 2001, 294: 2368–71
[111] Persons DA. Hematopoietic stem cell gene transfer for the treatment
of hemoglobin disorders. Hematology Am Soc Hematol Educ Program, 2009, 690–97
[112] Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia
mouse model with iPS cells generated from autologous skin. Science, 2007, 318: 1920–23
[113] Field JJ, Macklin EA, Yan Y, et al. Sibling history of asthma is a risk
factor for pain in children with sickle cell anemia. Am J Hematol, 2008, 83: 855–57
[114] Hargrave DR, Wade A, Evans JP, et al, Kirkham FJ. Nocturnal oxygen
saturation and painful sickle cell crises in children. Blood, 2003, 101: 846–48
[115] Bartolucci P, El Murr T, Roudot-Thoraval F, et al. A randomized,
controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood, 2009, 114: 3742–47
[116] Jacobson SJ, Kopecky BA, Joshi P, et al. Randomized trial of oral
morphine for painful episodes of sickle-cell disease in children. Lancet, 1997, 350: 1358–61
[117] National Confidential Enquiry into Patient Outcome and Death. A
sickle crisis? A report of the National Confidential Enquiry Into Patient Outcome And Death (2008). http://www.77cn.com.cn. uk/2008report1/Downloads/Sickle_report.pdf (accessed Jan 4, 2010)
[118] Griffin TC, McIntire D, Buchanan GR. High-dose intravenous
methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med, 1994, 330: 733–37
[119] Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188